April 1 (Reuters) - PACS Group said it is seeking a

valuation of as much as $3.25 billion in its U.S. initial public

offering, the latest in a string of firms looking to take

advantage of improving investor interest for new stocks.

After a two-year dry spell, IPOs in the United States are

expected to rebound in 2024 on firming bets of a soft landing

for the country's economy and a broad rally in the capital

markets.

The healthcare company is planning to sell 19.05 million

shares priced between $20 and $22 each to raise about $419

million at the top of the range, according to a regulatory

filing.

Founded in 2013, PACS is a post-acute healthcare company

primarily focused on delivering skilled nursing care through a

portfolio of independently operated facilities.

Citigroup, J.P. Morgan and Truist Securities are the lead

underwriters of the offering. It has applied to trade on the New

York Stock Exchange under the symbol "PACS".